![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, March 19, 2014 1:27:06 PM
Editor's Corner
The FDA vs. the flash mob: Hard questions as parents demand unproven drugs
By John Carroll
Last week the parents of 7-year-old Josh Hardy managed to whip up a media tempest big enough to get the biotech Chimerix ($CMRX) and the FDA to work out a pilot study so that their child could be treated after their compassionate use request was denied, alongside many others. Now the parents of another young boy afflicted by a terrible disease are using some interesting PR tactics in an attempt to achieve a much larger goal: Push the FDA to approve experimental drugs for Duchenne muscular dystrophy (DMD) ahead of pivotal studies in the hope that it could let their young son, Ryan Dunne, live a "healthy life."
The local CBS affiliate in Colorado turned out for a flash mob demonstration yesterday, with protesters chanting Ryan's name and giving his parents a chance to highlight their campaign to get 100,000 signatures together to push the FDA to make unapproved DMD drugs available to a young patient population with no therapies approved for the ultimately lethal muscle-wasting disease. Other parents have been turning out in large groups to give FDA officials an earful on the same point. And the "Race to Yes" campaign today added heat with their own statement backing the petition, which is specifically designed to get an accelerated approval for Sarepta's ($SRPT) eteplirsen.
"We don't have time to wait for the FDA," says Jennifer Dunne in her appeal at helpryandunne.com. "We need to do it now," says Ryan's father, adding that his son can't wait years for the FDA to act.
"Every day that the FDA stalls, Duchenne takes children's lives," said Tracy Seckler, the parent of a child with DMD, in a statement. "The FDA claims this is a priority, but they've been sending us the same bureaucratic form letter for several months. If they grant accelerated approval, our children could be the first generation of Duchenne patients to survive."
The campaign raises compelling questions. Does the FDA have a responsibility to allow children access to unproven drugs, provided there's evidence of their safety and the possibility of a positive outcome--of any kind? A group of companies, in particular Sarepta, Prosensa ($RNA) and PTC Therapeutics ($PTCT), have all provided some signals from the data that could indicate a benefit. But Sarepta only has data from a tiny study the agency has already questioned, looking to a pivotal study to decide whether the drug really works. Prosensa's drug failed a Phase III study conducted by GlaxoSmithKline ($GSK). PTC's earlier study for DMD also failed. And all three biotechs insist that there are compelling signs that the drugs may work for some of these boys.
If the FDA eventually decides to capitulate on this point, the biotechs would have a chance to market drugs to children. That could set up another showdown with restive private payers which may well reject covering drugs that are green-lighted without solid evidence of efficacy, approved under traditional guidelines. And that might leave parents to pay a high cost for unproven medications which may have no more effect on the disease than a placebo.
Parents and children don't want to hear about traditional guidelines when they reflect on what's happening to their child. The public will side with the victims, and that leaves the FDA caught between the high R&D standards it's mandated to uphold and the passions aroused by parents, the victims of disease and protesters.
There are no easy answers here. Just hard questions. -- John Carroll, editor-in-chief
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent RNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 08:07:00 PM
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 06/21/2024 08:05:00 PM
- Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day • PR Newswire (US) • 06/20/2024 01:00:00 PM
- Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 06/17/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 11:06:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:58:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:56:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:54:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:05:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:58:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 08:10:22 PM
- Avidity Biosciences to Participate in Upcoming Investor Conference • PR Newswire (US) • 06/14/2024 01:00:00 PM
- Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock • PR Newswire (US) • 06/14/2024 12:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 08:26:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 08:22:22 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/12/2024 08:19:05 PM
- Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock • PR Newswire (US) • 06/12/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 11:02:29 AM
- Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy • PR Newswire (US) • 06/12/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:46:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:27:15 PM
- Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress • PR Newswire (US) • 05/29/2024 08:05:00 PM
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/21/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:21:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:15:29 PM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM